Overview
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
Associated Conditions
- Advanced or Metastatic Breast Cancer
- Carcinoma of Gallbladder
- Cholangiocarcinoma
- Hepatocellular Carcinoma
- Locally Advanced Rectal Cancer (LARC)
- Metastatic Adenocarcinoma of the Gastroesophageal Junction
- Metastatic Gastric Cancers
- Metastatic Neuroendocrine Tumors
- Pancreatic Adenocarcinoma
- Pancreatic Cancer, Advanced or Metastatic
- Platinum-resistant Epithelial Ovarian Cancer
- Refractory Fallopian Tube Carcinoma
- Stage III Colon Cancer
- Unresectable or Metastatic Colorectal Cancer
- Metastatic pancreatic endocrine carcinoma
- Refractory peritoneal cancer
- Refractory, metastatic Colorectal carcinoma
- Unresectable, metastatic Esophageal Cancer
- Unresectable, metastatic Gastric Cancer
- Unresectable, metastatic Gastroesophageal Junction Cancer
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/02/23 | Phase 1 | Active, not recruiting | |||
2022/02/21 | Phase 2 | Active, not recruiting | |||
2022/02/21 | Phase 1 | Recruiting | |||
2022/02/14 | Early Phase 1 | Withdrawn | |||
2022/02/14 | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | ||
2022/02/11 | Phase 1 | UNKNOWN | |||
2022/02/11 | Phase 3 | Recruiting | Sun Yat-sen University | ||
2022/02/08 | Phase 2 | Recruiting | Zhen-Hai Lu | ||
2022/02/07 | Phase 2 | Withdrawn | MedSIR | ||
2022/01/31 | Phase 2 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||